iBio Faces NYSE American Delisting Threat

Ticker: IBIO · Form: 8-K · Filed: 2025-08-01T00:00:00.000Z

Sentiment: bearish

Topics: delisting, compliance, stock-exchange

Related Tickers: IBIO

TL;DR

NYSE American might kick iBio off the exchange, they have 10 days to fix it.

AI Summary

On July 29, 2025, iBio, Inc. filed an 8-K report indicating a potential delisting from the NYSE American. The company received a notice from the exchange regarding its failure to meet continued listing standards. iBio has 10 business days to submit a compliance plan.

Why It Matters

This filing signals potential financial distress or operational challenges for iBio, Inc., which could impact its stock value and ability to raise capital.

Risk Assessment

Risk Level: high — Receiving a delisting notice from a major stock exchange indicates significant non-compliance with listing requirements, posing a substantial risk to the company's operations and investor confidence.

Key Numbers

Key Players & Entities

FAQ

What specific continued listing standards did iBio, Inc. fail to meet?

The filing does not specify the exact continued listing standards that iBio, Inc. failed to meet, only that a notice was received from the NYSE American.

What is the deadline for iBio, Inc. to submit a compliance plan?

iBio, Inc. has 10 business days from the date of the notice to submit a compliance plan to the NYSE American.

What is the potential consequence if iBio, Inc. cannot regain compliance?

If iBio, Inc. cannot regain compliance with the NYSE American's listing standards, its securities may be delisted from the exchange.

Has iBio, Inc. previously received such notices?

The filing does not provide information on whether iBio, Inc. has previously received similar notices from the NYSE American.

What is the company's primary business?

iBio, Inc. is in the Pharmaceutical Preparations industry, as indicated by its Standard Industrial Classification code [2834].

From the Filing

0001558370-25-009992.txt : 20250801 0001558370-25-009992.hdr.sgml : 20250801 20250801164729 ACCESSION NUMBER: 0001558370-25-009992 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250729 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20250801 DATE AS OF CHANGE: 20250801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 251176831 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 ibio-20250729x8k.htm 8-K iBio, Inc._July 29, 2025 0001420720 false 0001420720 2025-07-29 2025-07-29 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 29, 2025 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) ​ ​ 001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.) ​ 11750 Sorrento Valley Road, Suite 200 San Diego , California 92121 (Address of principal executive offices and zip code) ( 979 ) 446-0027 (Registrant’s telephone number including area code) N/A (Former Name and Former Address) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions: ☐       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐       Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) ☐       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock , $0.001 par value per share IBIO The Nasdaq Stock Market LLC ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ​ ​ ​ ​ Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. ​ On July 29, 2025, iBio, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days (June 13, 2025 to July 28, 2025), the Company’s common stock did not maintain a minimu

View on Read The Filing